#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Update in andrological endocrinology


Authors: L. Stárka
Published in the journal: Urol List 2008; 6(4): 54-58

Summary

The aim of the study was to review actual problems and recent findings in andrological endocrinology. Present guidelines for testosterone treatment of hypogonadism, especially in aging males, and for the methodology of androgen determination are discussed. Important andvances higlighted mechanisms for internalisation of SHBG-bound testosterone into the target cell, therapeutic possibilities for paternity of men with Klinefelter’s syndrome, secular trends in decline of testosterone levels, prevention of prostate diseases of aging men, male hormonal contraception, andrological aspect of other diseases, esp. of disturbed thyroid function, and the role of human feromones for gender identity.

Key words:
testosterone, therapy, secular trends, prostate, Klinefelter’s syndrom, male contraception, human feromones


Zdroje

1. Hu LQ. Future development of andrology in China. Zhonghua Nan Ke Xue 2005; 11(1): 3–6.

2. Artiukhin AA. The role of andrology as a field of reproductive medicine in the solution of demographic problems in Russia. Vestn Ross Akad Med Nauk 2007; (11): 50–52.

3. Isidori A. The history of modern andrology. Med Secoli 2001; 13(2): 255–268.

4. Kubícek V. The present status of andrology in the Czech Republic. Cas Lek Cesk 2002; 141(2): 61–64.

5. Bhasin S, Cunnigham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995– 2010.

6. The Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril. 2004; 82 Suppl 1: S46–50.

7. Ritzén EM, Bergh A, Bjerknes R, Christiansen P, Cortes D, Haugen SE, Jörgensen N, Kollin C, Lindahl S, Läckgren G, Main KM, Nordenskjöld A, Rajpert-De Meyts E, Söder O, Taskinen S, Thorsson A, Thorup J, Toppari J, Virtanen H. Nordic consensus on treatment of undescended testes. Acta Paediatr. 2007; 96(5): 638–643.

8. Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology. Revised guidelines for human embryology and andrology laboratories. Fertil Steril. 2006; 86(5 Suppl): S57–72.

9. Simoni M, Bakker E, Krausz C. EAA/EMQN best practice guidelines for molecular diagnosis of y-chromosomal microdeletions. State of the art 2004. Int J Androl 2004; 27(4): 240–249.

10. Handelsman DJ. Update in andrology. J Clin Endocrinol Metab 2007; 92(12): 4505–4511.

11. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006; 296(19): 2351–2361.

12. Sakhri S, Gooren LJ. Safety aspects of androgen treatment with 5alpha-dihydrotestosterone. Andrologia 2007; 39(6): 216–222.

13. Tindall Dj, Rittmaster RS. Rationale for Inhibiting 5alpha-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer. J Urol. 2008; 179(4): 1235–1242.

14. Barnard RJ. Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr. 2007; 86(3): 889–893.

15. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U. PLCO Trial. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98(4): 245–254.

16. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epdemiol 2008; 167(8): 925–934.

17. Stacewicz-Sapuntzakis M, Borthakur G, Burns JL, Bowen PE. Correlations of dietary patterns with prostate health. Mol Nutr Food Res 2008; 52(1): 114–130.

18. Khan N, Afaq F, Mukhtar H. Cancer Chemoprevention through dietary antioxidants: Progress and Promise. Antioxid Redox Signal 2008; 10(3): 475–510.

19. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 2007; 12: 4839–4854.

20. Harada N, Murata Y, Yamaji R, Miura T, Inui H, Nakano Y. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2008; 53(6): 556–560.

21. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24(5A): 2783–2840.

22. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92(2): 405–413.

23. Lin BC, Scanlan TS. Few things in life are „free“: cellular uptake of steroid hormones by an active transport mechanism. Mol Interv. 2005; 5(6): 338–340.

24. Hammes A, Andreassen TK, Spoelgen R et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122(5): 751–762.

25. Kozyraki R, Goffolt F. Multiligand endocytosis and congenital defects: roles of cubilin, megalin and amnionless. Curr Pharm Des 2007; 13(29): 3038-3046.

26. Skakkebaek NE, Jorgensen N, Main KM, Rajpert-De Meyts E, Leffers H, Andersson AM, Juul A, Carlsen E, Mortensen GK, Jensen TK, Toppari J. Is human fecundity declining? Int J Androl 2006; 29(1): 2–11.

27. Andersson AM, Jorgensen N, Main KM, Toppari J, Rajpert-De Meyts E, Leffers H, Juul A, Jensen TK, Skakkebaek NE. Adverse trends in male reproductive health: we may have reached a crucial 'tipping point'. Int J Androl 2008; 31(2): 74–80.

28. Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab 2007; 92(1): 196–202.

29. Andersson AM, Jensen TK, Juul A, Petersen JH, Jorgensen T, Skakkebaek NE. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. J Clin Endocrinol Metab 2007; 92(12): 4696–4705.

30. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Hormonal Male Contraception Summit Group. Rate, extent and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006; 367: 1412–1420.

31. Heráček J, Urban M, Sobotka V, Lukeš M, Bittner L, Novotný T, Otava Z. Mužská antikoncepce. Urol Listy 2007; 5: 2–33.

32. Amory JK. Contraceptive developments for men. Drugs Today (Barc). 2007; 43(3): 179–192.

33. Bojensen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome; a Danish register study based on hospital discharge diagnoses. Clin Endocrinol Metab 2006; 91: 1254–1260.

34. Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab 2005; 88: 6516–6522.

35. Handelsman DJ, Liu PY. Klinefelters syndrome: a microcosmos of male reproductive health. J Clin Endocrinol Metab 2006; 91: 1220–1222.

36. Lafranco F, Kamischke A, Zitzmann M, Nieschalg E. Klinefelters syndrome. Lancet 2004; 364: 273–283.

37. Schiff JD, Palermo GD, Veeck LL, Goldstein M, Rosenwaks Z, Schlegel PN. Success of testicular sperm injection and intracytoplasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab 2005; 90: 6263–6267.

38. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90(12): 6472–6479.

39. Meeker JD, Godfrey-Bailey L, Hauser R. Relationships between serum hormone levels and semen quality among men from an infertility clinic. J Androl. 2007; 28(3): 397–406.

40. Veronelli A, Masu A, Ranieri R, Rognoni C, Laneri M, Pontiroli AE. Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. Int J Impot Res 2006; 18(1): 111–114.

41. Chatterjee S, Chowdhury RG, Khan B. Medical management of male infertility. J Indian Med Assoc. 2006; 104(2): 74, 76–77.

42. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, Heufelder A, Jones H, Meryn S, Zitzmann M. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 2008; 62(5): 791–798.

43. Balercia G, Boscaro M, Lombardo F, Carosa E, Lenzi A, Jannini EA. Sexual symptoms in endocrine diseases: psychosomatic perspectives. Psychother Psychosom 2007; 76(3): 134–140.

44. Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007; 369(9561): 597–611.

45. Savic I, Berglund H, Lindström P. Brain response to putative pheromones in homosexual men. Proc Natl Acad Sci U S A 2005; 102(20): 7356-7361.

46. Berglund H, Lindström P, Savic I. Brain response to putative pheromones in lesbian women. Proc Natl Acad Sci U S A. 2006; 103(21): 8269–8274.

47. Berglund H, Lindström P, Dhejne-Helmy C, Savic I. Male-to-female transsexuals show sex-atypical hypothalamus activation when smelling odorous steroids. Cereb Cortex 2007 Dec 3.Metab 2006; 91: 1995– 2010.

Štítky
Paediatric urologist Urology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#